CureVac マネジメント

マネジメント基準チェック /24

CureVacの CEO はAlexander Zehnderで、 Apr2023年に任命され、の在任期間は 1.58年です。の年間総報酬は€ 978.33Kで、 51.1%給与と48.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.025%を直接所有しており、その価値は€ 153.29K 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と8.7年です。

主要情報

Alexander Zehnder

最高経営責任者

€978.3k

報酬総額

CEO給与比率	51.1%
CEO在任期間	1.6yrs
CEOの所有権	0.03%
経営陣の平均在職期間	1.8yrs
取締役会の平均在任期間	8.7yrs

経営陣の近況

Recent updates

CEO報酬分析

CureVac の収益と比較して、Alexander Zehnder の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€278m
Mar 31 2024	n/a	n/a	-€273m
Dec 31 2023	€978k	€500k	-€260m

報酬と市場: Alexanderの総報酬 ($USD 1.03M ) は、 German市場 ($USD 1.42M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Alexanderの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Alexander Zehnder (54 yo)

1.6yrs

在職期間

€978,331

報酬

Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Alexander Zehnder	CEO, MD & Member of Management Board	1.6yrs	€978.33k	0.025% € 153.3k
Malte Greune	COO, Member of Management Board & MD	3.3yrs	€600.74k	0.0038% € 23.2k
Myriam Mendila	Chief Scientific Officer	1.8yrs	€614.49k	0.0021% € 12.9k
Ulrike Gnad-Vogt	Senior VP & Area Head of Oncology	1.8yrs	€284.15k	データなし
Axel-Sven Malkomes	Chief Financial Officer	no data	データなし	データなし
Sarah Fakih	Vice President Corporate Communications & Investor Relations	no data	データなし	データなし
Marco Rau	General Counsel	no data	データなし	データなし
Thorsten Schuller	Head of Corporate Communications	no data	データなし	データなし
Slavica Stevanovic-Heck	Head of Human Resources	no data	データなし	データなし
Patrick Baumhof	Senior Vice President of Technology	no data	データなし	データなし
Ronald Plasterk	Senior Vice President of Science & Innovation	no data	データなし	データなし
Marcus Dalton	Head of Intellectual Property	no data	データなし	データなし

1.8yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: 5CVの経営陣は経験豊富とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Hans-Georg Rammensee	Scientific Director of Immunology and Member of Scientific Advisory Board	no data	データなし	データなし
Craig Tooman	Supervisory Board Member	5.4yrs	€96.25k	0.0043% € 26.2k
Karim Fizazi	Member of Scientific Advisory Board	8.7yrs	データなし	データなし
Michael Brosnan	Independent Director of Supervisory Board	1.4yrs	€51.03k	0.0019% € 11.4k
Baron Stephenne	Independent Chairman of Supervisory Board	9.3yrs	€123.75k	0.0075% € 45.6k
Nina Bhardwaj	Member of Scientific Advisory Board	8.7yrs	データなし	データなし
Stanley Plotkin	Member of Scientific Advisory Board	8.7yrs	データなし	データなし
Michael Manns	Member of Scientific Advisory Board	8.7yrs	データなし	データなし
Jean-Paul Prieels	Member of Scientific Advisory Board	8.7yrs	データなし	データなし
Mathias Hothum	Supervisory Board Member	9.3yrs	€96.25k	0.0048% € 29.5k
Dirk Jäger	Member of Scientific Advisory Board	8.7yrs	データなし	データなし
Christopher Karp	Member of Scientific Advisory Board	8.7yrs	データなし	データなし

8.7yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: 5CVの取締役会は経験豊富であると考えられます ( 8.7年の平均在任期間)。

CureVac マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Curevac N.V. Appoints Axel Sven Malkomes as Chief Financial Officer, Effective November 11, 2024

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. Announces Executive Changes

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

Recent updates

Forecast to breakeven in 2024

CureVac N.V. to Report Q3, 2024 Results on Nov 12, 2024

Curevac N.V. Appoints Axel Sven Malkomes as Chief Financial Officer, Effective November 11, 2024

CureVac N.V. to Present at the Society for Immunotherapy of Cancer 39th Annual Meeting

CureVac N.V. to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Second quarter 2024 earnings released: €0.32 loss per share (vs €0.30 loss in 2Q 2023)

CureVac N.V. Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac N.V. to Report Q2, 2024 Results on Aug 15, 2024

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

New major risk - Financial position

CureVac N.V. to Report Q1, 2024 Results on May 23, 2024

Full year 2023 earnings released: €1.18 loss per share (vs €1.32 loss in FY 2022)

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024

CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Third quarter 2023 earnings released: €0.25 loss per share (vs €0.25 loss in 3Q 2022)

CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: €0.30 loss per share (vs €0.31 loss in 2Q 2022)

CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023

CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. Announces Executive Changes

CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

First quarter 2023 earnings released: €0.27 loss per share (vs €0.081 loss in 1Q 2022)

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Full year 2022 earnings released: €1.32 loss per share (vs €2.21 loss in FY 2021)

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs

CureVac N.V. Announces CEO Changes

Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021)

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022

Second quarter 2022 earnings released: €0.31 loss per share (vs €0.82 loss in 2Q 2021)

No longer forecast to breakeven

CureVac Announces Executive Changes

CureVac N.V. Announces Board Changes

CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.

CureVac N.V. Announces Changes of CDO

CureVac N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings released: €2.21 loss per share (vs €0.98 loss in FY 2020)

Forecast breakeven date pushed back to 2024

CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022

CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK

CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV

CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023

CureVac Streamlines European Network for mRNA Product Manufacturing

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Forecast breakeven moved forward to 2021

CureVac Announces that Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

CureVac N.V. Announces Results from the Final Analysis of its 40,000 Subject International Pivotal Phase 2b/3 Study of the First-Generation COVID-19 Vaccine Candidate, CVnCoV

CureVac N.V. Announces Results of the Second Interim Analysis of its International Pivotal Phase 2b/3 Study in Approximatively 40,000 Subjects

CureVac N.V.’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

CureVac N.V. Develops a New Class of Transformative Medicines Based on Messenger Ribonucleic Acid

Full year 2020 earnings released: €0.98 loss per share (vs €137 loss in FY 2019)

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24